In the last few years, there has been a dramatic increase in telemedicine, remote diagnoses, and prescribed treatment. The demand for these services highlighted their profound benefits, not only as a contingency but as a new modus operandi. But why stop at reactionary treatment?
Another consequence of the pandemic is the realization that we need to rethink the way we develop and deliver new drugs. Perhaps inspired by the rise of blockchain technology, the pharmaceutical industry has embraced the role of decentralization. As a result, many companies are now exploring the impact of Decentralized Clinical Trials (DCTs). New FDA guidance, increasing success of sponsorship, the removal of appointment conflicts, and streamlined data collection are just some of the major benefits.
Clinical trials are “pivotal” phases of drug development. Throughout the years, they’ve enabled patients across the world to access innovative therapies, advanced research, and medical knowledge.
Our Experts
Damien Vossion
Vice President at Capgemini Invent, Life Sciences & Operating Model
I started my career as a consultant in 2000 and gained experience in major transformation projects in Manufacturing, Quality, Supply Chain, and clinical operations, with a strong focus on Industry 4.0 since 2015. I supported General Management in the Life Sciences sector (Pharmaceutical companies, Medical Device companies, and Chemical companies) as well as other large industrial and services companies. I now manage the Life Sciences department at Capgemini Invent in France and co-develop the Life Sciences in Switzerland.
